Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation
- PMID: 12885812
- DOI: 10.1200/JCO.2003.02.563
Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation
Abstract
Purpose: To explore the efficacy and safety of three regimens of weekly paclitaxel plus carboplatin as initial therapy and the feasibility of subsequent maintenance therapy versus observation in patients with advanced non-small-cell lung cancer (NSCLC).
Patients and methods: Four hundred one patients were randomly assigned to one of the following arms: arm 1, paclitaxel 100 mg/m2 weekly for 3 of 4 weeks with carboplatin (area under the curve [AUC] = 6) on day 1; arm 2, paclitaxel 100 mg/m2 and carboplatin (AUC = 2) weekly for 3 of 4 weeks; or arm 3, paclitaxel 150 mg/m2 cycle 1 and 100 mg/m2 cycle 2 and carboplatin (AUC = 2) weekly for 6 of 8 weeks. Patients who responded (n = 130) at week 16 were randomly assigned to either weekly paclitaxel therapy (70 mg/m2, 3 of 4 weeks; n = 65) or observation (n = 65).
Results: For the 390 assessable patients, the objective response rates observed with initial therapy were 32% for arm 1, 24% for arm 2, and 18% for arm 3. The median time to progression and median survival times were 30 and 49 weeks for arm 1, 21 and 31 weeks for arm 2, and 27 and 40 weeks for arm 3, respectively. The 1-year survival rates were 47% for arm 1, 31% for arm 2, and 41% for arm 3.
Conclusion: Arm 1, paclitaxel 100 mg/m2 weekly for 3 of 4 weeks with carboplatin (AUC = 6) administered on day 1, demonstrates the most favorable therapeutic index in patients with advanced NSCLC.
Similar articles
-
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.J Clin Oncol. 2008 Jan 20;26(3):468-73. doi: 10.1200/JCO.2007.13.1912. J Clin Oncol. 2008. PMID: 18202422 Clinical Trial.
-
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.Cancer. 2008 Aug 1;113(3):542-6. doi: 10.1002/cncr.23583. Cancer. 2008. PMID: 18512224 Clinical Trial.
-
Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.Lung Cancer. 2007 Nov;58(2):238-45. doi: 10.1016/j.lungcan.2007.06.003. Epub 2007 Jul 20. Lung Cancer. 2007. PMID: 17658655 Clinical Trial.
-
Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.Jpn J Clin Oncol. 2005 Apr;35(4):188-94. doi: 10.1093/jjco/hyi059. Jpn J Clin Oncol. 2005. PMID: 15845567 Review.
-
Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.J Clin Oncol. 2005 Jun 1;23(16):3760-7. doi: 10.1200/JCO.2005.09.108. Epub 2005 Apr 18. J Clin Oncol. 2005. PMID: 15837967 Review.
Cited by
-
Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).Ann Oncol. 2013 Jun;24(6):1534-42. doi: 10.1093/annonc/mdt123. Epub 2013 Apr 4. Ann Oncol. 2013. PMID: 23559150 Free PMC article. Clinical Trial.
-
Maintenance Therapy for NSCLC: Consensus and Controversy.Chin J Cancer Res. 2011 Dec;23(4):254-8. doi: 10.1007/s11670-011-0254-5. Chin J Cancer Res. 2011. PMID: 23359213 Free PMC article.
-
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer.BMC Res Notes. 2013 Jan 3;6:3. doi: 10.1186/1756-0500-6-3. BMC Res Notes. 2013. PMID: 23281805 Free PMC article. Clinical Trial.
-
Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.BMC Cancer. 2005 Jan 25;5:10. doi: 10.1186/1471-2407-5-10. BMC Cancer. 2005. PMID: 15667664 Free PMC article.
-
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.Invest New Drugs. 2018 Oct;36(5):903-910. doi: 10.1007/s10637-018-0617-6. Epub 2018 May 30. Invest New Drugs. 2018. PMID: 29846848 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
